van Doorslaer E. et al., The redistributive effect of health care finance in twelve OECD countries, „Journal of Health Economics” 1999; 18, 3: 291–313.
What are the equity, efficiency, cost containment and choice implications of private health-care funding in western Europe? „World Health Organization” 2004: 19.
Hermanowski T., Udział własny pacjenta jako metoda ograniczania pokusy nadużywania leków refundowanych, Konferencja WZ, 2009.
Gemmill M.C., Thomson S., Mossialos E., What impact do prescription drug charges have on efficiency and equity? Evidence from high-income countries, „International Journal for Equity in Health” 2008; 7, 12: 1–22.
Goldman P.D., Joyce G.F., Zheng Y., Prescription Drug Cost Sharing, Associations with medication and medical utilization and spending and health, „American Medical Association” 2007; 298, 1: 61–68.
Gibson T.B., Ozminowski R.J., Goetzel R.Z., The Effects of Prescription Drug Cost Sharing: A Review of the Evidence, „The American Journal of Managed Care” 2005; 11, 11: 730–740.
Lexchin J., Grootendorst P., Effects of prescription drug user fees on drug and health services use and on health status in vulnerable populations a systematic review of the evidence, „International Journal of Health Services” 2004; 34, 1: 101–122.
Morris S., Devlin N., Parkin D., Ekonomia w ochronie zdrowia, Wydawnictwo Wolters Kluwer Polska, Warszawa 2011.
O’Donnell O. et al., Analyzing Health Equity Using Household Survey Data: A Guide to Techniques and their Implementation, The World Bank, Waszyngton 2008: 193.
Wagstaff A. et al., Equity in finance of health care: some further international comparisons, „Journal of Health Economics” 1999; 18, 3: 263–290.
Gaál P. et al., Hungary: Health System in Review, „Health System in Transition” 2011; 13, 5: 1–226.
Baji P. et al., Changes in Equity in Out-of-pocket Payments during the Period of Health Care Reforms: Evidence from Hungary, „International Journal for Equity in Health” 2012, 1: 36–46.
Sagan A. et al., Poland: Health System in Review, „Health Systems in Transition” 2011; 13, 8: 1–193.
Łuczak J., García-Gomez P., Financial burden of drug expenditures in Poland, „Health Policy” 2012; 105, 3: 256–264.
Olejaz M. et al., Denmark: Health System in Review, „Health Systems in Transition” 2012; 14, 2: 1–192.
Møller-Pedersen T., Pricing and reimbursement of drugs in Denmark, „European Journal of Health Economics” 2003; 4, 1: 60–65.
Gundgaard J., Income related inequality in prescription drugs in Denmark, „Pharmacoepidemiology and Drug Safety” 2005; 14, 5: 307–317.
Thomson S, Mossialos E., Primary Care and Prescription Drugs: Coverage, Cost-Sharing, and Financial Protection in Six European Countries, „Issue Brief (Commonwealth Fund)” 2010; 182: 1–14.
Pilkiewicz M., Rynek farmaceutyczny 2012 – wpływ nowej ustawy refundacyjnej na konsumpcję leków w Polsce, IMS Health, Warszawa 2012; http://www.bcc.org.pl/uploads/media/BCC_IMS_2012-05-08_Rynek_Farmaceutyczny_2012_Nowe_Prawox.pdf; dostęp: 28.11.2013.
Minister Zdrowia, Projekt założeń do projektu ustawy o refundacji leków, środków spożywczych specjalnego przeznaczenia żywieniowego oraz wyrobów medycznych oraz niektórych innych ustaw, Warszawa 2013; http://www.mz.gov.pl/wwwfiles/ma_struktura/docs/projzalust_20130430_ust.pdf; dostęp: 15.05.2013.